Management of Acute Coronary Syndrome in Patients with Elevated Liver Enzymes

Initial Assessment and Risk Stratification

The European Society of Cardiology recommends measuring high-sensitivity cardiac troponin T or I, serum creatinine, hemoglobin, hematocrit, platelet count, blood glucose, and liver function tests including SGPT/ALT in patients with acute coronary syndrome 2
Assess for high-risk features requiring early invasive management: recurrent ischemia, hemodynamic instability, major arrhythmias, diabetes mellitus, or elevated troponin levels, as recommended by the European Society of Cardiology 3, 2

The European Society of Cardiology recommends administering aspirin to all patients without contraindications 4, 5
Add P2Y12 inhibitor (clopidogrel, ticagrelor, or prasugrel) for dual antiplatelet therapy (DAPT), as recommended by the European Society of Cardiology 5, 6
Consider proton pump inhibitor in patients at high risk of gastrointestinal bleeding, as recommended by the European Society of Cardiology 1
Use fondaparinux, enoxaparin, or unfractionated heparin as appropriate based on bleeding risk, as recommended by the European Society of Cardiology 5, 6
Monitor liver function tests regularly when using anticoagulants in patients with elevated SGPT/ALT, as recommended by the European Society of Cardiology 2
Initiate high-intensity statin therapy early (within 1-4 days) after admission in all ACS patients, regardless of baseline cholesterol levels, as recommended by the European Society of Cardiology 1
Target LDL-C reduction of ≥50% from baseline and achieve LDL-C <1.4 mmol/L (<55 mg/dL), as recommended by the European Society of Cardiology 1
Administer beta-blockers in patients with LVEF ≤40% or heart failure, unless contraindicated, as recommended by the European Society of Cardiology 4, 8
Prescribe ACE inhibitors within 24 hours in patients with LVEF ≤40%, heart failure, hypertension, or diabetes, unless contraindicated, as recommended by the European Society of Cardiology 8, 9

Obtain baseline liver function tests before initiating pharmacotherapy, as recommended by the European Society of Cardiology 2
Monitor liver function tests regularly during hospital stay and follow-up, as recommended by the European Society of Cardiology 2
Consider dose adjustment or alternative medications if significant worsening of liver function occurs, as recommended by the European Society of Cardiology 7
Avoid hepatotoxic medications when possible, as recommended by the European Society of Cardiology 2
Evaluate for underlying liver disease that may require specific management, as recommended by the European Society of Cardiology 2

Advise lifestyle changes including smoking cessation, regular physical activity, and healthy diet, as recommended by the European Society of Cardiology 4, 2
Continue DAPT for recommended duration based on patient risk and stent type, as recommended by the European Society of Cardiology 5
Maintain statin therapy long-term with regular monitoring of liver function, as recommended by the European Society of Cardiology 1, 7
Target blood pressure control with diastolic BP <90 mmHg (<85 mmHg in diabetic patients), as recommended by the European Society of Cardiology 4
Enroll patients in cardiac rehabilitation programs, as recommended by the European Society of Cardiology 4